Skip to main content
Revolution Medicines Inc.
Healthcare · Biotechnology
Made on Aug 19, 2026
Price at call $214.66
6-month call Neutral -1.2%
Target by Feb 2027 $212.00
Great value below $150.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change -1.2% to $212.00
Predicted High $228.00 at 2 months
Predicted Low $205.00 at 5 months
Max Drawdown (predicted) -4.5%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 19, 2026 11:40 pm
Neutral RVMD trends range-bound to $212.00 (-1.2% from $214.66) by Feb 2027. ride-then-fade
ThesisRVMD is a pre-profit narrative RAS platform story with no value anchor, riding a risk-on tape and +116% six-month momentum. Near-term drift stays supported by the strong sentiment and monopoly-narrative bid, but value/quality lenses are deeply negative and any regime cooling or KRAS-adjacent data disappointment can compress this high-beta name meaningfully by year-end.
Invalidated ifBreak below $170 on volume, or a competitive KRAS/RAS clinical setback, or regime flip to risk-off would invalidate the drift-higher-then-fade path.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $214.66 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Aug 19, 2026 $214.66 at call The anchor — every point below is measured from this price and date.
2 weeks Sep 2, 2026 $196.87–$232.45 typical range · internal point $218.50 ±8.3% 6/10 Momentum and risk-on regime sustain near-term drift higher
What actually happened: closed $209.87 on Sep 1, 2026 = -2.2% vs the call (predicted +1.8%)  ·  direction HIT (called flat, was flat)  ·  off by 4.0 pp  ·  accuracy 8/10  ·  typical range ±8.3%: inside the band  ·  S&P -1.0% over the same window — lagged it
1 month Sep 19, 2026 $188.87–$240.45 typical range · internal point $223.00 ±12.0% 5/10 Narrative bid persists absent catalyst, low-vol grind
2 months Oct 19, 2026 $228.00 +6.2% 4/10 Q3 print window; beat cadence supports modest extension
3 months Nov 19, 2026 $221.00 +3.0% 4/10 Post-earnings digestion, valuation gravity begins pressing
4 months Dec 19, 2026 $210.00 -2.2% 3/10 Year-end profit-taking on 100%+ YTD winner
5 months Jan 19, 2027 $205.00 -4.5% 3/10 January rotation away from expensive story names
6 months Feb 19, 2027 $212.00 -1.2% 3/10 Stabilization near prior base as buyers return

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $0.00 (+0.0%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 1 degraded · 6 notes — follow the chain top-down (cause → effect).
  • Degraded
    No usable fair-value anchor — brain-only (anchorless) mode: no v0.3 control line, prediction reasons from lenses/sentiment/regime/price behaviour.
    value_anchor
  • Note
    No positive earnings — traditional DCF and EPV are not applicable
    upstream:classification
  • Note
    Valuation is inherently speculative — based on revenue multiples and growth assumptions
    upstream:classification
  • Note
    Valuation anchor absent: composite_fair_value.
    anchor:composite_fair_value
  • Note
    Valuation anchor absent: dcf.
    anchor:dcf
  • Note
    Valuation anchor absent: anchored_pe.
    anchor:anchored_pe
  • Note
    Valuation anchor absent: signal_adjusted.
    anchor:signal_adjusted

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$214.66
Composite fair value
Signal-adjusted fair value
DCF fair value
Anchored-PE fair value
Buy-below (value lens)
Value net score-69
Value confidence7 / 10
Quality net score-60
Memo confidence— / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 39.5%  3m 41.6%  6m 64.7%  
Daily σ (realism noise)2.6%
Beta vs S&P 500 1m 0.07  3m 0.92  5m 1.19  
Trailing 6-month return116.4%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #8eb3df85c300

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Aug 19, 2026 freshest RVMD-20260819-122747-7209
ext-forensic-memo Aug 19, 2026 freshest ext-RVMD-20260819-224319-29e8
ext-lens-quality Aug 19, 2026 freshest ext-RVMD-20260819-224319-29e8
ext-lens-sentiment Aug 19, 2026 freshest ext-RVMD-20260819-224319-29e8
ext-lens-value Aug 19, 2026 freshest ext-RVMD-20260819-224319-29e8
valuation-synthesis Aug 19, 2026 freshest RVMD-20260819-122747-7209

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

1 frozen snapshot — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 19, 2026 v0.6.0 Neutral $214.66 $212.00 -1.2% Feb 2027 viewing

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.